Accretion Pharmaceuticals Limited (NSE:ACCPL)

Market Cap	1.31B
Revenue (ttm)	898.18M +56.5%
Net Income	96.68M +42.3%
EPS	9.03 +6.5%
Shares Out	11.12M
PE Ratio	13.01
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,200
Open	118.00
Previous Close	117.10
Day's Range	114.35 - 120.00
52-Week Range	53.80 - 127.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 8, 2026

About Accretion Pharmaceuticals

Accretion Pharmaceuticals Limited engages in the manufacturing and marketing of pharmaceutical products in India. The company offers antibiotic, antibacterial, antifungal, anti-inflammatory, anti-spasmodic, antihistamine, antiallergy, anticough, anticold, antiulcer, gastrointestinal, antacid, anti-diabetic, cardiac, anti-hypertensive, psychotropic, memory enhancer, vitamins, supplements, and other products. It also provides external preparation, oral powder, effervescent formulation, and nutraceutical products, as well as formulations for brain...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 125
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ACCPL

Financial Performance

In fiscal year 2026, Accretion Pharmaceuticals's revenue was 898.18 million, an increase of 56.54% compared to the previous year's 573.76 million. Earnings were 96.68 million, an increase of 42.31%.